The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Overview: Rituximab is used for certain cancers, rheumatoid arthritis, and certain immune conditions. The most common side effects of rituximab are nausea, infections, headaches, and feeling weak ...

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Monjuvi® (tafasitamab ...

Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low tumor burden follicular lymphoma can substantially delay the need for ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory ...

Rituximab, a chimeric monoclonal antibody specific for CD20, targets and destroys both normal and malignant B cells. This drug was initially approved by the FDA for the treatment of patients with ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...